FDA clears GSK and Ionis hepatitis B therapy with functional-cure goal
The FDA approved bepirovirsen, marketed as Hibsago, for chronic hepatitis B. The decision came ahead of expectations and positions the GSK and Ionis drug for potential blockbuster sales. It is intended to provide a functional cure.
The FDA has approved bepirovirsen, which will be sold as Hibsago, for people with chronic hepatitis B. The therapy comes from GSK and Ionis and was cleared earlier than expected.
The drug is intended to pursue a functional cure, a goal that shapes how it may be viewed commercially. The companies’ positioning suggests potential blockbuster sales.
For people with chronic hepatitis B, the approval could add a therapy explicitly aimed at a functional cure, potentially changing how patients and clinicians discuss treatment goals. Its anticipated commercial scale may draw attention from health systems and payers, though the societal effect will depend on evidence, pricing, and availability.